Presentations given this week at the American College of Rheumatology Annual Meeting in Boston discuss a variety of advances in RA treatment. Rheumatologists at Geisinger Health System in Central Pennsylvania have developed a new model of rheumatoid arthritis patient care that is designed to improve quality while reducing costs. The AIM FARTHER care model is described as an industry-vetted problem solving and quality improvement methodology that delivers better care at lower cost, from reduced use of costly biologic drugs.
Separately at the Annual Meeting, a Netherlands-based research team reported that a TNF inhibitor dose-reduction strategy can be just as effective at safely treating RA patients as regular dosing methods, while also saving approximately $7,500 per patient annually. In addition to expense, TNF inhibitors like adalimumab (Humira®) or etanercept (Enbrel®) may have side effects that make dose reduction or discontinuation an attractive option when possible.